Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies-Reference-Cited by-同舟云学术

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies

Published:2019-02-09 Issue:6 Volume:13 Page:725-734
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Panaccione Remo¹,Löfberg Robert²,Rutgeerts Paul³,Sandborn William J⁴,Schreiber Stefan⁵,Berg Sofie⁶,Maa Jen-Fue⁷,Petersson Joel⁸,Robinson Anne M⁷,Colombel Jean-Frederic⁹

Affiliation:

1. University of Calgary, Department of Medicine, Calgary, AB, Canada

2. IBD Unit, Karolinska Institutet, Stockholm, Sweden

3. Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium

4. Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA

5. Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany

6. Global Medical Affairs, AbbVie AB, Solna, Sweden

7. Development, AbbVie Inc., North Chicago, IL, USA

8. Global Medical Affairs, AbbVie Inc., North Chicago, IL, USA

9. Division of Gastroenterology, Icahn School of Medicine at Mt Sinai, New York, NY, USA

Funder

AbbVie

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/13/6/725/28705400/jjy223.pdf

Reference30 articles.

1. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort;Thia;Gastroenterology,2010

2. Crohn’s disease;Torres;Lancet,2017

3. Management strategies to improve outcomes of patients with inflammatory bowel diseases;Colombel;Gastroenterology,2017

4. Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016. Part 1: diagnosis and medical management;Gomollón;J Crohns Colitis,2017

5. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis;Hazlewood;Gastroenterology,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease;European Journal of Clinical Pharmacology;2024-03-30

2. Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies;Gastro Hep Advances;2024

3. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review;World Journal of Gastroenterology;2023-08-07

4. Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges;Alimentary Pharmacology & Therapeutics;2023-06-29

5. Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis;European Journal of Medical Research;2022-09-30